Protocol for evaluating survival outcomes of once-daily versus twice-daily radiotherapy with chemotherapy in LS-SCLC patients, indicating potential treatment optimization.
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of once-daily radiotherapy versus twice-daily radiotherapy concurrently with chemotherapy for optimal survival outcomes in people with limited-stage small-cell lung cancer (LS-SCLC).
No takes yet. Share an insight, caveat, or question.
Harada et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: